Fingerprint
Dive into the research topics of 'Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically